Jason M. Melear

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Farshad Nassiri, Vikas Patil, Leeor Yefet et al. · Nature Medicine · 2023 · 232 citations · Full text

Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders1

Jason M. Melear, Robert M. Goldstein, Marlon F. Levy et al. · Transplantation · 2002 · 86 citations

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: <scp>LYRA</scp> study

Habte Yimer, Jason M. Melear, Edward A. Faber et al. · British Journal of Haematology · 2019 · 66 citations · Full text

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

R. Charles Coombes, Sacha J. Howell, Simon Lord et al. · Nature Communications · 2023 · 54 citations · Full text